In Section A, participants will receive diverse doses and schedules of oral ABBV-744 tablet to detect Safe and sound dosing program. Added participants will likely be enrolled with the discovered monotherapy dosign program. In Phase B, individuals will receive oral ruxolitinib and ABBV-744 will be specified as "increase-on" therapy. In https://dominickykwgt.azzablog.com/32082964/getting-my-abbv-744-brd4-inhibitor-clinical-efficacy-in-refractory-cancers-to-work